PARP-2 inhibitors (Fujisawa)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NamePARP-2 inhibitors (Fujisawa)
Drug Alias NameFR-261529
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPoly (ADP-Ribose) polymerase inhibitors
TargetsPoly (ADP-Ribose) polymerase
Therapy Area/IndicationsNerve DegenerationParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesFujisawa Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsNerve DegenerationParkinson Disease

Other Information

ATC CodeN/A
Related LinksN/A